These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. Filip V; Kolibás E J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658 [TBL] [Abstract][Full Text] [Related]
3. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835 [TBL] [Abstract][Full Text] [Related]
7. The use of selegiline in Alzheimer's patients with behavior problems. Goad DL; Davis CM; Liem P; Fuselier CC; McCormack JR; Olsen KM J Clin Psychiatry; 1991 Aug; 52(8):342-5. PubMed ID: 1907964 [TBL] [Abstract][Full Text] [Related]
8. Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use. Simpson GM; Frederickson E; Palmer R; Pi E; Sloane RB; White K Biol Psychiatry; 1985 Jun; 20(6):684-7. PubMed ID: 3922441 [No Abstract] [Full Text] [Related]
9. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial. Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159 [TBL] [Abstract][Full Text] [Related]
10. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911 [TBL] [Abstract][Full Text] [Related]
11. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Monteverde A; Gnemmi P; Rossi F; Monteverde A; Finali GC Clin Ther; 1990; 12(4):315-22. PubMed ID: 2121360 [TBL] [Abstract][Full Text] [Related]
12. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506 [TBL] [Abstract][Full Text] [Related]
13. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Piccinin GL; Finali G; Piccirilli M Clin Neuropharmacol; 1990 Apr; 13(2):147-63. PubMed ID: 2109658 [TBL] [Abstract][Full Text] [Related]
14. Brief information on an early phase-II study with deprenyl in demented patients. Martini E; Pataky I; Szilágyi K; Venter V Pharmacopsychiatry; 1987 Nov; 20(6):256-7. PubMed ID: 3124143 [TBL] [Abstract][Full Text] [Related]
15. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263 [TBL] [Abstract][Full Text] [Related]
16. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Schneider LS; Olin JT; Pawluczyk S Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085 [TBL] [Abstract][Full Text] [Related]
17. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585 [TBL] [Abstract][Full Text] [Related]
18. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects. Freedman M; Rewilak D; Xerri T; Cohen S; Gordon AS; Shandling M; Logan AG Neurology; 1998 Mar; 50(3):660-8. PubMed ID: 9521253 [TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598 [TBL] [Abstract][Full Text] [Related]
20. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]